Cadila Healthcare Gains 2% on USFDA Nod for Oseltamivir Powder
Shares of Cadila Healthcare rose 2 percent intraday Monday as it has received USFDA final approval for Oseltamivir powder.
Neshar Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6mg/ml which is used in the treatment and prevention of influenza.
The powder will be produced at the Neshar Pharmaceuticals' manufacturing facility at located at St. Louis, MO, USA.
According to IMS data, the sales of the Oseltamivir powder for oral suspension are estimated at USD 367.92 million.
The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
At 14:22 hrs Cadila Healthcare was quoting at Rs 486, up Rs 4.80, or 1 percent on the BSE.
Disclaimer: Echemi reserves the right of final explanation and revision for all the information.